Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generate BiomedicinesGENB +4.48%6 Receivables Turnover is 103.55 as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 843 Biotechnology companies, Generate Biomedicines ranks better than 97.27% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Generate Biomedicines's Revenue for the
six
months ended in Dec. 2025 was $31.89 Mil. Generate Biomedicines's average Accounts Receivable for the
six
months ended in Dec. 2025 was $0.31 Mil.
Hence, Generate Biomedicines's Receivables Turnover for the
six
months ended in Dec. 2025 was 103.55.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Generate Biomedicines Receivables Turnover Related Terms
Generate Biomedicines Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Generate Biomedicines's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines Receivables Turnover Chart
Generate Biomedicines Annual Data
Trend
Dec24
Dec25
Receivables Turnover
66.43
103.55
Generate Biomedicines Semi-Annual Data
Dec24
Dec25
Receivables Turnover
66.43
103.55
GENB vs ZYME, DMRA, SLBT: Receivables Turnover Comparison
For the Biotechnology subindustry, Generate Biomedicines's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Generate Biomedicines Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Generate Biomedicines's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a Receivables Turnover of 103.55 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #23 out of 843 companies in the Biotechnology industry, placing it in the top 2.7%.
Is Generate Biomedicines' Receivables Turnover too high?
Generate Biomedicines' current Receivables Turnover is 103.55. The Biotechnology industry median Receivables Turnover is 5.27. Generate Biomedicines' value of 103.55 is 1864.9% above this industry median. Based on the distribution chart, Generate Biomedicines ranks #23 out of 843 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Receivables Turnover compare to ZYME and DMRA?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #23 out of 843 companies for Receivables Turnover. This places Generate Biomedicines in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.27. Generate Biomedicines' value of 103.55 is 1864.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Generate Biomedicines's current Receivables Turnover of 103.55 is 1864.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Generate Biomedicines and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Generate Biomedicines's current Receivables Turnover is 103.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Receivables Turnover of 103.55. The current Receivables Turnover is 103.55 and 1864.9% above the Biotechnology industry median of 5.27. Generate Biomedicines' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Receivables Turnover is 103.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 
